Is Dxcm overvalued?
At 24x revenue and 245x forward earnings, DexCom is priced at a level where the company is expected to produce both double-digit revenue growth and continued margin expansion for the next 5+ years, leading the company to be grossly overvalued today.
Is DexCom public?
(NASDAQ:DXCM – News) today announced the initial public offering of 4,700,000 shares of common stock at a price of $12.00 per share. DexCom is selling all of the shares in the offering.
How many shares does DexCom have?
Shares Outstanding Range, Past 5 Years
| Minimum | 84.60M | Dec 31 2016 |
|---|---|---|
| Maximum | 96.75M | Jul 22 2021 |
| Average | 90.63M |
Will Dxcm go up?
Will De stock price grow / rise / go up? Yes. The DXCM stock price can go up from 591.960 USD to 779.294 USD in one year.
Is Dxcm a buy?
DexCom has received a consensus rating of Buy. The company’s average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.
Can you buy stock in DexCom?
Dexcom, Inc. , you can buy DexCom Inc stock in any dollar amount, or any other fund or stock you know on Stash.
Is Dxcm stock a buy?
DexCom has received a consensus rating of Buy.
Is dexcom stock overpriced?
DexCom is trading at a premium to its fair price. Given the financial targets the management has set for the company up to 2025, the company’s current stock price looks too high.
How high does dexcom go?
Dexcom Inc (NASDAQ:DXCM) The 17 analysts offering 12-month price forecasts for Dexcom Inc have a median target of 630.00, with a high estimate of 750.00 and a low estimate of 575.00.
Will DXCM go up?
Is DXCM a good investment?
Is DXCM a good stock to buy?
The financial health and growth prospects of DXCM, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Should you buy Dexcom (DXCM) stock right now?
The following two stocks are absolutely sizzling right now, but they also both boast superior businesses with strong competitive advantages that generate and sustain consistent demand and robust profits. Medical device maker DexCom (NASDAQ: DXCM) may not be a household name for many investors, but it should be.
What are analysts’ price targets for Dexcom’s stock?
Their forecasts range from $438.00 to $550.00. On average, they anticipate DexCom’s stock price to reach $500.80 in the next year. This suggests that the stock has a possible downside of 7.7%. View analysts’ price targets for DexCom or view top-rated stocks among Wall Street analysts.
How has covid-19 affected dexdexcom’s stock?
DexCom’s stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 114.9% and is now trading at $542.43. View which stocks have been most impacted by COVID-19.
What is Dexcom’s return on equity (ROE)?
DexCom had a net margin of 24.45% and a trailing twelve-month return on equity of 16.17%. View DexCom’s earnings history. How has DexCom’s stock been impacted by COVID-19 (Coronavirus)?
